<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04313634</url>
  </required_header>
  <id_info>
    <org_study_id>18-010546</org_study_id>
    <nct_id>NCT04313634</nct_id>
  </id_info>
  <brief_title>Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans</brief_title>
  <official_title>Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans: A Phase 2, Single-Center, 20-week, Open-Label, Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sundeep Khosla, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if senolytic drugs reduce senescent cell burden and reduce bone resorption
      markers/increase bone formation markers in elderly women.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Changes in C-terminal telopeptide of type I collagen [CTX]</measure>
    <time_frame>Baseline, 20 weeks</time_frame>
    <description>Percent changes in serum bone turnover markers C-terminal telopeptide of type I collagen [CTX]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Changes in amino-terminal propeptide of type I collagen [P1NP]</measure>
    <time_frame>Baseline, 20 weeks</time_frame>
    <description>Percent changes in serum bone turnover markers amino-terminal propeptide of type I collagen [P1NP]</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dasatinib plus Quercetin Treatment Goup</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Dasatinib (D; 100 mg for two days) plus Quercetin (Q; 1000 mg total daily for three consecutive days taken orally on an intermittent schedule (starting every 28 days) with no-therapy periods in between dosing regimens, repeated every 28 days over 20 weeks, resulting in five total dosing periods throughout the entire intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fisetin Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Fisetin (F; ~20 mg/kg/day for three consecutive days) taken orally on an intermittent schedule (starting every 28 days) with no-therapy periods in between dosing regimens, repeated every 28 days over 20 weeks, resulting in five total dosing periods throughout the entire intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will not receive any intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Dasatinib will be supplied as 100 mg tablet white to off-white, biconvex, oval, film- coated</description>
    <arm_group_label>Dasatinib plus Quercetin Treatment Goup</arm_group_label>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quercetin</intervention_name>
    <description>Quercetin will be supplied as quercetin phytosome (sophora japonica concentrate (leaf) / phosphatidylcholine complex from Sunflower) 250 mg</description>
    <arm_group_label>Dasatinib plus Quercetin Treatment Goup</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fisetin</intervention_name>
    <description>Fisetin will be supplied in 100 mg capsules to be administered orally</description>
    <arm_group_label>Fisetin Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able and willing to provide informed consent.

          -  Normal postmenopausal women

          -  Aged ≥70 years

        Exclusion Criteria:

          -  Hemoglobin A1c ≥8.0%

          -  Abnormal screening labs (see below)

          -  Presence of significant liver or kidney disease

          -  Presence of heart failure

          -  Malignancy (including myeloma)

          -  Malabsorption, including gastric bypass / reduction, Crohn's disease

          -  Subjects who are diabetic and on insulin, sulfonylureas or SGLT2 inhibitors. Diabetes
             alone or Metformin use are not grounds for exclusion.

          -  Hyperthyroidism

          -  Acromegaly

          -  Cushing's syndrome

          -  Hypopituitarism

          -  Subjects with a fracture within the past six months

          -  Undergoing treatment with any medications that affect bone turnover, including the
             following:

               -  adrenocorticosteroids (&gt; 3 months at any time or &gt; 10 days within the previous
                  yr), anticonvulsant therapy (within the previous year),

               -  calcium supplementation of &gt; 1200 mg/d (within the preceding 3 months),

               -  bisphosphonates (within the past 3 yrs),

               -  denosumab,

               -  estrogen (E) therapy or treatment with a selective E receptor modulator, or
                  teriparatide (within the past yr)

               -  β-blockers

          -  QTc &gt;450 msec

          -  Inability to provide consent

          -  Inability to tolerate oral medication

          -  eGFR&lt;30 ml/min/1.73 m2

          -  Subjects on therapeutic doses of anti-coagulants (e.g. warfarin, heparin, low
             molecular weight heparin, factor Xa inhibitors, etc)

          -  Subjects with hypovitaminosis D (25-hydroxyvitamin D [25(OH)D] &lt;20 ng/ml, whose level
             does not improve above 20 ng/ml after two courses of 8-week treatment of 1000 IU/d of
             Vitamin D. They will be referred to their primary provider should this occur.

          -  Subjects taking anti-arrhythmic medications known to cause QTc prolongation

          -  Subjects taking potentially senolytic agents within the last 6 months: Fisetin,
             Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax

          -  Subjects currently taking drugs that induce cellular senescence: alkylating agents,
             anthracyclines, platins, other chemotherapy

          -  Subjects taking H2 antagonists

          -  Tyrosine kinase inhibitor therapy

          -  Subjects not having a PBTL p16INK4a mRNA expression level &gt;95 percentile of young
             female controls (this cut-off is depicted by the dotted line in Fig. 6)

          -  Known hypersensitivity or allergy to Dasatinib, Quercetin, or Fisetin

          -  Subjects taking the following antimicrobial agents: Aminoglycosides, Azole antifungals
             (fluconazole, miconazole, voriconazole, itraconazole), Macrolides (clarithromycin,
             erythromycin), Antivirals (nelfinavir, indinavir, saquinavir, ritonavir,
             elbasvir/grazoprevir), Rifampin

          -  Subjects taking the following other drugs if they cannot be held for at least 2 days
             before and during administration of Fisetin: digoxin, lithium, all statins,
             repaglidine, bosentan, gemfibrozil, olmesartan, enalapril, valsartan, methotrexate,
             corticosteroids, eluxadoline, eltrombopag, nitroglycerin, pioglitazone, glyburide,
             enzalutamide, ezetimibe, colchicine, imatinib, cyclosporine, tacolimus, sirolimus,
             carbamazepine, flecainide, phenytoin, phenobarbital, rifampicin, theophylline,
             warfarin, heparin, full dose ASA, clopidogrel, celecoxib, desipramine, thioridazine,
             venlafaxine, tizanidine, atomoxetine, voriconazole, citalopram, diazepam,
             escitalopram, propranolol, clozapine, cyclobenzaprine, mexiletine, olanzapine,
             ondansetron, riluzole,

          -  Subjects taking medications that are sensitive to substrates or substrates with a
             narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or
             inducers of CYP3A4 (e.g., cyclosporine, tacrolimus or sirolimus). If antifungals are
             absolutely necessary from an infectious disease perspective, then they will be allowed
             only if the levels are therapeutic.

          -  Subjects taking strong inhibitors of CYP3A4

          -  Subjects on antiplatelet agents (Clopidogrel [Plavix]; Dipyridamole + Asprin
             [Aggrenox]; Ticagrelor [Brilinta]; Prasugrel [Effient]; Ticlopidine [Ticlid] or Other)
             who are unable or unwilling to reduce or hold therapy prior to and during the study
             drug dosing periods. Subjects may continue their previous regimen between study drug
             dosing periods.

          -  Subjects on quinolone antibiotic therapy for treatment or for prevention of infections
             within ten days.

          -  Subjects taking proton pump inhibitors and unwilling to discontinue therapy for two
             days before and during the study drug dosing periods.

          -  Subjects with clinically evident fluid retention

          -  Subjects with evidence of right heart strain on ECG

          -  Subjects with a history of pulmonary hypertension

          -  Subjects with an abnormal Complete Blood Count (clinically insignificant changes would
             be acceptable based on the judgement of the investigators)

          -  Presence of any condition the Investigator believes would place the subject at risk or
             would preclude the subject from successfully completing all aspects of the trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sundeep Khosla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tammie Volkman, RN</last_name>
    <phone>507-538-6023</phone>
    <email>volkman.tammie@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joshua Farr, PhD</last_name>
    <email>farr.joshua@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Sundeep Khosla, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

